Oncology healthtech has become one of the most active areas of healthcare venture capital since 2020. Investment is flowing into AI-driven cancer diagnostics, precision oncology, genomics, liquid biopsy, digital pathology, clinical-trial technology, oncology data platforms and computational drug discovery.
Know Who Is Investing, What Is Moving And What Customers Want Next. Download Sample: https://www.towardshealthcare.com/download-sample/5920
The most active investors are not all traditional digital-health funds. Many are specialist life-sciences VCs investing across the intersection of cancer biology, software, diagnostics and AI.
A 2024 PitchBook snapshot identified RA Capital Management as the most active investor by deal count among the listed oncology healthtech investors since 2020, with 15 deals, followed by Keiretsu Forum and SOSV with 12 deals each, and Polaris Partners and Catalio Capital Management with 11 each.
Among the most strategically important names is GV, Alphabet’s venture capital arm, which has built a substantial healthcare and life-sciences portfolio spanning oncology data, precision medicine, diagnostics and AI.
Top VC Investors to Watch Since 2020
| Investor | Reported oncology healthtech deal activity since 2020* | Core strength | Key focus |
|---|---|---|---|
| RA Capital Management | 15 deals | Life sciences | Oncology therapeutics, biotech |
| Keiretsu Forum | 12 deals | Broad investor network | Early to growth-stage healthcare |
| SOSV | 12 deals | Early-stage investing | Deep tech, biotech |
| Polaris Partners | 11 deals | Healthcare and biotech | Therapeutics, diagnostics |
| Catalio Capital Management | 11 deals | Life sciences | Oncology and biotech |
| NLC Ventures Netherlands | 10 deals | Health innovation | Healthtech and medtech |
| Peregrine Ventures | 10 deals | Medtech | Healthcare technologies |
| Northpond Ventures | 10 deals | Science and technology | Diagnostics and life sciences |
| High-Tech Gründerfonds | 9 deals | Early-stage innovation | Deep tech and life sciences |
| Vida Ventures | 8 deals | Biotechnology | Precision medicine and therapeutics |
*Deal counts in this table are from PitchBook’s global oncology healthtech snapshot, covering activity since 2020 and reported as of August 27, 2024.
1. RA Capital Management – A Leading Oncology Life-Sciences Investor
RA Capital Management stands out as the highest-ranked investor by deal count in PitchBook’s oncology healthtech snapshot, with 15 reported deals since 2020.
The firm’s strength is its deep focus on biotechnology and life sciences, making it particularly relevant for companies operating between traditional oncology drug development and technology-enabled precision medicine.
Why RA Capital matters
RA Capital is well positioned for companies developing:
- Precision oncology platforms
- Cancer therapeutics
- Genomics technologies
- Biomarker-driven treatments
- AI-enabled drug discovery
- Clinical-stage biotechnology
Strength: Deep scientific and clinical investment expertise.
Limitation: It is generally a better fit for science-intensive companies than purely software-focused oncology startups.
2. Polaris Partners – Strong Biotech and Healthcare Experience
Polaris Partners recorded 11 oncology healthtech deals in PitchBook’s snapshot.
The firm has a long history across healthcare and biotechnology and is particularly relevant for companies moving from scientific discovery toward clinical development.
Key areas
- Oncology therapeutics
- Biotechnology
- Diagnostics
- Drug discovery
- Precision medicine
Polaris also appears alongside GV and other major investors in several biotech financings, reflecting the highly collaborative nature of large life-sciences rounds.
Strength: Strong experience across company formation and life-sciences development.
Limitation: Not exclusively focused on oncology software or digital health.
3. Catalio Capital Management – Science-Driven Healthcare Investing
Catalio Capital Management recorded 11 deals in the PitchBook oncology healthtech dataset.
The firm is particularly relevant to companies combining:
- Biomedical science
- Therapeutics
- Clinical data
- Advanced diagnostics
- Healthcare technology
Why it matters
Cancer innovation increasingly requires investors capable of understanding both scientific development and commercial healthcare infrastructure.
Catalio fits this hybrid profile.
Strength: Life-sciences specialization.
Limitation: Companies seeking very large late-stage technology-growth rounds may need additional growth-equity partners.
4. Northpond Ventures – Diagnostics and Data Opportunity
Northpond Ventures recorded 10 oncology healthtech deals in the PitchBook analysis.
The firm is particularly relevant to the growing overlap between:
Science + diagnostics + data + computational technology
This makes it important for oncology companies developing:
- Molecular diagnostics
- Genomics
- Precision medicine
- AI-enabled biology
- Clinical data platforms
Strength: Strong fit for science-intensive platforms.
Limitation: Portfolio fit is likely more important than simply being an oncology company.
5. Peregrine Ventures – Medtech and Healthcare Innovation
Peregrine Ventures recorded 10 deals in the oncology healthtech dataset.
The firm is particularly relevant for companies developing technologies that sit closer to the medical-device and clinical-technology side of oncology.
Potential areas include:
- Cancer diagnostics
- Medical devices
- Imaging
- Clinical technologies
- Hospital-based innovation
Strength: Healthcare technology experience.
Limitation: Less relevant for companies focused exclusively on software without a strong clinical or technological component.
GV (Google Ventures): Why It Deserves Special Attention
GV is not the highest-ranked firm by PitchBook’s 2020–2024 oncology healthtech deal-count table, but it is one of the most influential investors across the broader healthcare, AI and life-sciences ecosystem.
GV began investing in healthcare in 2009 and invests across therapeutics, diagnostics, medical devices and health technology. Its portfolio includes companies such as Foundation Medicine, Flatiron Health, Beam Therapeutics and Verve Therapeutics.
GV’s healthcare investment scale
GV reported that it had invested approximately $1 billion in healthcare since the beginning of 2020 in earlier disclosures.
More recent industry reporting estimates that GV has deployed approximately $1.3 billion into healthcare and life-science companies since 2020.
GV also states that it has partnered with 20 AI healthcare companies, including companies using AI to improve drug discovery and healthcare delivery.
GV’s Oncology and Cancer-Relevant Track Record
GV’s portfolio is particularly important because it includes companies that have helped shape modern oncology infrastructure.
Flatiron Health
Flatiron Health became one of the best-known oncology data and technology companies, building software and real-world evidence infrastructure for cancer care.
GV lists Flatiron Health as a portfolio investment and exit.
Foundation Medicine
Foundation Medicine helped establish the commercial importance of comprehensive genomic profiling and precision oncology.
GV also lists Foundation Medicine as a portfolio investment and exit.
Why these investments matter
Together, these examples show GV’s interest in the broader oncology technology stack:
Genomic profiling → clinical data → precision medicine → treatment decision-making
That makes GV particularly relevant for founders developing technology platforms rather than only single-drug assets.
GV’s Competitive Advantage
GV operates at the intersection of:
- Artificial intelligence
- Healthcare technology
- Computational biology
- Diagnostics
- Therapeutics
- Precision medicine
The firm says its healthcare and life-sciences team includes physicians, scientists and operators, while its broader investment platform benefits from deep technology expertise.
Recent GV investment activity
GV investors have continued participating in large healthcare and life-sciences rounds.
For example, GV-backed investments recorded by investor databases include:
- Parabilis Medicines — $310 million Series F in January 2026
- Gate Bioscience — $65 million Series B in November 2025
- BBOT — $200 million financing in May 2024
- Seismic Therapeutic — $120 million Series B in December 2023
- Dyno Therapeutics — $100 million Series A in May 2021
These examples represent broader healthcare and biotechnology activity and should not all be classified as oncology investments.
GV at a Glance
| Metric | Data |
|---|---|
| Healthcare investing began | 2009 |
| Healthcare investment since 2020 | ~$1B reported historically |
| Industry estimate since 2020 | ~$1.3B |
| AI healthcare companies partnered with | 20 |
| Core healthcare areas | Therapeutics, diagnostics, devices, healthtech |
| Notable oncology-related exits | Flatiron Health, Foundation Medicine |
Other Major Investors With Strong Oncology Relevance
PitchBook deal counts provide one view of activity, but they do not capture every influential investor.
Several other firms deserve attention because of their broad oncology, biotech and healthtech portfolios.
ARCH Venture Partners
ARCH is one of the most important company-creation investors in biotechnology.
Its strategy is particularly relevant to:
- Oncology therapeutics
- Synthetic biology
- Computational biology
- New drug modalities
- Platform biotechnology
ARCH is frequently involved in large, science-intensive financing rounds alongside firms such as GV and Andreessen Horowitz.
General Catalyst
General Catalyst is particularly important on the healthcare technology and AI side.
For oncology healthtech, its relevance includes:
- AI infrastructure
- Healthcare software
- Care delivery
- Clinical data
- Technology-enabled services
This makes it a stronger candidate for digital oncology platforms than for every traditional therapeutic company.
Andreessen Horowitz (a16z Bio + Health)
Andreessen Horowitz invests across:
- Biotechnology
- AI
- Healthcare software
- Computational biology
- Digital health
The firm’s healthcare investors have participated in major life-sciences and healthcare financings alongside GV and other specialist funds.
NEA
NEA remains one of the largest and most diversified healthcare and life-sciences investors.
Its scale allows investment across:
- Early-stage biotechnology
- Growth-stage healthcare
- Medical technology
- Therapeutics
- Digital health
Khosla Ventures
Khosla Ventures is particularly important for AI-first healthcare innovation.
The firm has been active across:
- AI diagnostics
- Computational biology
- Healthcare software
- Automation
- Digital health
For oncology healthtech founders building highly differentiated AI platforms, Khosla can be a strategically relevant investor.
Estimated Broader Oncology Investment Activity
A recent industry overview estimated broader historical oncology-related investment activity across oncology software, diagnostics, genomics, AI, digital pathology and precision medicine as follows:
| Investor | Estimated oncology-related investments* |
|---|---|
| OrbiMed | 95+ |
| RA Capital Management | 90+ |
| ARCH Venture Partners | 85+ |
| Third Rock Ventures | 80+ |
| F-Prime Capital | 75+ |
| General Catalyst | 70+ |
| Andreessen Horowitz | 65+ |
| NEA | 60+ |
| Sofinnova Partners | 60+ |
| Casdin Capital | 55+ |
| GV | 50+ |
*These are broad estimated historical oncology-related investment counts and are not directly comparable with PitchBook’s deal counts since 2020.
Where Is Oncology HealthTech VC Money Going?
Since 2020, investor attention has increasingly focused on several areas.
1. AI in Oncology
AI is being used for:
- Medical imaging
- Digital pathology
- Cancer detection
- Drug discovery
- Clinical decision support
- Trial matching
GV says it has partnered with 20 AI healthcare companies, highlighting the increasing convergence of AI and life sciences.
2. Precision Oncology
Investors continue to support technologies involving:
- Genomic profiling
- Biomarkers
- Molecular diagnostics
- Personalized treatment selection
Foundation Medicine is one of the clearest examples of how precision oncology became a major technology and investment category.
3. Oncology Data Platforms
Cancer generates large volumes of:
- Clinical data
- Genomic data
- Imaging data
- Treatment data
- Real-world evidence
Companies that can organize and analyze these datasets are attracting both technology and life-sciences investors.
4. Liquid Biopsy and Early Detection
Cancer detection remains one of the highest-potential areas for investment.
Investors are looking at:
- Blood-based diagnostics
- Multi-cancer detection
- Molecular screening
- AI-enabled detection
GV’s healthcare portfolio has included cancer-testing company Grail, illustrating the firm’s historical exposure to this area.
5. Computational Drug Discovery
AI is increasingly being used to identify:
- Drug targets
- New molecules
- Biomarkers
- Patient subgroups
This is bringing traditional oncology investors and technology-focused investors into the same financing rounds.
Investor Comparison: Which VC Fits Which Oncology Startup?
| Startup type | Best-fit investor profile | Examples |
|---|---|---|
| Cancer therapeutics | Specialist life-sciences VC | RA Capital, ARCH, Polaris |
| AI drug discovery | TechBio investor | GV, a16z, ARCH |
| Oncology diagnostics | Science + technology investor | Northpond, GV |
| Digital pathology | AI and healthcare VC | GV, General Catalyst |
| Cancer-care software | Digital-health VC | General Catalyst, GV |
| Precision oncology | Genomics and life-sciences VC | RA Capital, Polaris, GV |
| Early-stage science | Company-creation investor | ARCH, SOSV |
| Growth-stage platform | Large multi-stage investor | NEA, GV, General Catalyst |
The Numbers Investors Should Watch
The broader oncology healthtech ecosystem is becoming increasingly concentrated among experienced investors.
One industry estimate suggests:
- The top 5 investors account for approximately 29% of estimated oncology investment activity.
- The top 10 account for approximately 52%.
- The top 25 account for approximately 78%.
These estimates cover a broader historical oncology investment universe and should be interpreted as directional rather than a standardized global deal-count ranking.
Why GV Remains One of the Most Important Names
GV may not lead every oncology-specific deal-count ranking.
However, it has several advantages that make it particularly important:
- ~$1B–$1.3B healthcare and life-sciences investment since 2020
- Experience across AI and healthcare
- Portfolio exposure to Flatiron Health and Foundation Medicine
- 20 AI healthcare company partnerships
- Ability to invest across therapeutics, diagnostics and healthtech
- Access to deep technology expertise through its broader ecosystem
The Strategic Takeaway
The top oncology healthtech investors since 2020 are not defined by one investment style.
RA Capital and Polaris bring deep life-sciences expertise.
ARCH and Third Rock are important company builders.
General Catalyst and a16z bring healthcare technology and AI capabilities.
And GV stands out for connecting AI, precision medicine, diagnostics and healthcare technology.
For oncology founders, the best investor is therefore not necessarily the one with the highest number of cancer deals.
The more important question is:
Does the investor understand the scientific, clinical, regulatory and commercial challenges of your specific oncology technology?
How Towards Healthcare Research & Consulting Can Help
Towards Healthcare Research & Consulting can help companies and investors track:
- Oncology VC deals
- Investor portfolios
- Funding rounds
- AI oncology companies
- Cancer diagnostics
- Precision oncology platforms
- Digital pathology
- Clinical trial technology
- Company valuations
- M&A activity
- Emerging cancer technologies
The objective is to connect investment activity, technology development and clinical innovation to identify where the next oncology opportunities may emerge.
Connect with us for complete guidance or further enquiry at [email protected]
Europe Region – +44 778 256 0738
North America Region – +1 8044 4193 44
APAC Region: +91 9356 9282 04
Visit Our Website: https://www.towardshealthcare.com
Find us on social platforms: LinkedIn | Twitter | Instagram | Medium